|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||38.99 - 40.46|
|52 Week Range||24.45 - 41.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.27|
This article is from today’s FT Opinion email. Sign up to receive a daily digest of the big issues straight to your inbox. Africa is on the verge of a demographic explosion. While populations in Europe ...
Westminster’s Science and Technology Committee said the devices were a “useful tool in the NHS anti-smoking arsenal”. Some maintain, however, that the UK — and England in particular — is out of step with international opinion. , the San Francisco-based vaping start-up that has just launched in the UK, has spooked regulators who are launching a prevention campaign targeting 10m youths who vape or are open to trying it.
For anyone who thinks the UK’s exit from the EU has been proceeding in a haphazard fashion, spare a thought for Milan. In November, following bids from a range of European cities, Milan tied with Amsterdam in a vote by EU foreign ministers. The winner — pulled out of a hat — was Amsterdam.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnLink ...
Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Medicines Co. (MDCO) delivered earnings and revenue surprises of 1.56% and -78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Parsippany, New Jersey-based company said it had a loss of 74 cents per share. Losses, adjusted for one-time gains and costs, were 63 cents per share. The results beat Wall Street expectations. The ...
Medicines Co. (MDCO) reported second-quarter financial results early Wednesday, including a smaller-than-expected profit loss and a revenue miss. Medicines Co. had $162.5 million in cash and cash equivalents as of June 30, compared with $515.4 million at the end of last year.
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Medicines Company (NASDAQ: MDCO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. ...
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).
The Medicines Company will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT to discuss its second-quarter 2018 financial results and operational developments.
Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump’s criticism of Pfizer is having an impact on how other companies set their prices. “By putting pressure on one particular company, I think all the companies are saying: We don’t want to be Pfizer,” Denner said at the Delivering Alpha Conference. Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies “should be ashamed” for the hikes.
Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.
The Delivering Alpha 2018 conference took place Wednesday in New York, and this year’s event included a number of Wall Street heavy-hitters. Benzinga Pro reported live from Delivering Alpha all day long, ...
Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
CNBC's Dominic Chu reports on Sarissa Capital Management's Alex Denner presenting his best investment ideas at Delivering Alpha.